CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: METTL2A (ImmuneEditome ID:339175)

1. Gene summary of enriched editing regions for METTL2A

check button Gene summary
Gene informationGene symbol

METTL2A

Gene ID

339175

GeneSynonymsMETTL2
GeneCytomap

17q23.2

GeneTypeprotein-coding
GeneDescriptiontRNA N(3)-methylcytidine methyltransferase METTL2A|methyltransferase 2A, methylcytidine|methyltransferase like 2A|methyltransferase-like protein 2A
GeneModificationdate20230524
UniprotIDQ96IZ6;A0A087WW35
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr17:62428876-62429024:+ENST00000333483.13ENSG00000087995.14METTL2AncRNA_intronicAluJochr17:62428876-62429024:+.alignment
chr17:62442331-62443208:+ENST00000333483.13ENSG00000087995.14METTL2AncRNA_intronicAluJr,AluSzchr17:62442331-62443208:+.alignment
chr17:62449407-62450854:+ENST00000311506.8ENSG00000087995.14METTL2AUTR3AluSx1,AluSc8,AluSq2,AluJr4,(T)nchr17:62449407-62450854:+.alignment
chr17:62449407-62450854:+ENST00000616852.1ENSG00000087995.14METTL2AUTR3AluSx1,AluSc8,AluSq2,AluJr4,(T)nchr17:62449407-62450854:+.alignment


Top

2. Tumor-specific enriched editing regions for METTL2A


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr17:62449407-62450854:+KICHEER1.8542e-05image
ENSG00000087995.14,METTL2AKICHEAG1.8542e-05image
chr17:62449407-62450854:+LUADEER9.7261e-03image
ENSG00000087995.14,METTL2ALUADEAG2.2867e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000087995.14,METTL2AKIRPPathEAG4.9077e-024.5939e-020.1309image
chr17:62449407-62450854:+KIRPPathEER4.4638e-024.9453e-020.1289image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
ENSG00000087995.14,METTL2ATHCAEAG1.6674e-021.8416e-025.0362e+04image

Top

3. Enriched editing regions and immune related genes for METTL2A


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr17:62449407-62450854:+STADEERENSG00000266200,PNLIPRP20.15643.7618e-022.6125e-280.5622imageNNNAMonocytes
chr17:62449407-62450854:+ESCAEERENSG00000233429,HOTAIRM10.29362.3457e-023.1052e-070.4033imageNNHOTAIRM1Plasma_cellsGSVA_HALLMARK_MITOTIC_SPINDLE
chr17:62449407-62450854:+TGCTEERENSG00000008128,CDK11A0.31038.2234e-035.5097e-080.4645imageNNCDK11AMacrophages_M2GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY
chr17:62449407-62450854:+TGCTEERENSG00000227154,MKRNP20.26772.5810e-022.6278e-070.4427imageNNNAB_cells_naiveGSVA_HALLMARK_ANGIOGENESIS
chr17:62449407-62450854:+TGCTEERENSG00000174652,ZNF2660.24683.5423e-024.0112e-060.4006imageNNNAB_cells_naiveGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS
chr17:62449407-62450854:+THYMEERENSG00000196810,CTBP1-AS20.44573.6102e-041.2921e-050.4311imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_PROTEIN_SECRETION
chr17:62449407-62450854:+THYMEERENSG00000162407,PPAP2B0.44053.9157e-041.2116e-070.5110imageNNPPAP2BT_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
chr17:62449407-62450854:+THYMEERENSG00000163608,C3orf170.42206.8323e-043.5091e-060.4555imageNNNAT_cells_CD4_memory_activatedGSVA_HALLMARK_PROTEIN_SECRETION
chr17:62449407-62450854:+THYMEERENSG00000131495,NDUFA2-0.40639.9801e-044.6483e-05-0.4051imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_DN
chr17:62449407-62450854:+THYMEERENSG00000188171,ZNF6260.39731.3686e-034.2910e-050.4068imageNNNAT_cells_CD4_memory_activatedGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr17:62449407-62450854:+STADEERENSG00000266200,PNLIPRP20.15643.7618e-022.6125e-280.5622imageNNNAMonocytes
chr17:62449407-62450854:+ESCAEERENSG00000233429,HOTAIRM10.29362.3457e-023.1052e-070.4033imageNNHOTAIRM1Plasma_cellsGSVA_HALLMARK_MITOTIC_SPINDLE
chr17:62449407-62450854:+TGCTEERENSG00000008128,CDK11A0.31038.2234e-035.5097e-080.4645imageNNCDK11AMacrophages_M2GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY
chr17:62449407-62450854:+TGCTEERENSG00000227154,MKRNP20.26772.5810e-022.6278e-070.4427imageNNNAB_cells_naiveGSVA_HALLMARK_ANGIOGENESIS
chr17:62449407-62450854:+TGCTEERENSG00000174652,ZNF2660.24683.5423e-024.0112e-060.4006imageNNNAB_cells_naiveGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS
chr17:62449407-62450854:+THYMEERENSG00000196810,CTBP1-AS20.44573.6102e-041.2921e-050.4311imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_PROTEIN_SECRETION
chr17:62449407-62450854:+THYMEERENSG00000162407,PPAP2B0.44053.9157e-041.2116e-070.5110imageNNPPAP2BT_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
chr17:62449407-62450854:+THYMEERENSG00000163608,C3orf170.42206.8323e-043.5091e-060.4555imageNNNAT_cells_CD4_memory_activatedGSVA_HALLMARK_PROTEIN_SECRETION
chr17:62449407-62450854:+THYMEERENSG00000131495,NDUFA2-0.40639.9801e-044.6483e-05-0.4051imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_DN
chr17:62449407-62450854:+THYMEERENSG00000188171,ZNF6260.39731.3686e-034.2910e-050.4068imageNNNAT_cells_CD4_memory_activatedGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

More results



Top

4. Enriched editing regions and immune related splicing for METTL2A


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000087995.14,METTL2A
CESCEAGA3ENSG00000077238.9chr1627340185:27340273:27342120:27342154:27341069:27342154-0.23602.5205e-021.0195e-10-0.4048imageNADAR;AIFM1;AUH;BUD13;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;LIN28;LIN28A;LIN28B;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184IL4RDendritic_cells_activated
ENSG00000087995.14,METTL2A
ESCAEAGIRENSG00000165637.9chr1075230574:75230774:75230897:75230951-0.15914.8619e-025.3291e-08-0.4986imageNADAR;AIFM1;AUH;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184NA
chr17:62449407-62450854:+
TGCTEERA3ENSG00000141756.14chr1741820353:41820461:41820946:41821089:41820706:41821089-0.30144.2710e-023.8552e-06-0.4028imageNNFKBP10B_cells_naiveGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000087995.14,METTL2A
TGCTEAGESENSG00000138073.9chr227131439:27131508:27131673:27131831:27132009:271320820.29201.2753e-026.8164e-050.4009imageNADAR;AIFM1;AUH;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184NAB_cells_naiveGSVA_HALLMARK_GLYCOLYSIS
chr17:62449407-62450854:+
TGCTEERIRENSG00000167107.8chr1750462387:50462585:50463155:504632510.38305.3100e-031.1014e-070.4567imageNNACSF2B_cells_naiveGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY
ENSG00000087995.14,METTL2A
TGCTEAGESENSG00000150991.10chr12124911647:124911952:124912180:124912278:124912408:1249125060.15993.2740e-027.4384e-060.4417imageNADAR;AIFM1;AUH;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184NA
ENSG00000087995.14,METTL2A
TGCTEAGIRENSG00000167107.8chr1750462387:50462585:50463155:504632510.37765.3314e-031.3242e-070.4541imageNADAR;AIFM1;AUH;BUD13;CNBP;CPSF6;CSTF2T;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LIN28;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184ACSF2B_cells_naiveGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY
chr17:62449407-62450854:+
TGCTEERESENSG00000150991.10chr12124911647:124911952:124912180:124912278:124912408:1249125060.15903.7530e-028.6970e-060.4387imageNNNA
chr17:62449407-62450854:+
TGCTEERIRENSG00000118418.10chr679201244:79201726:79202316:792023890.31703.1271e-023.5402e-060.4027imageNNNAB_cells_naiveGSVA_HALLMARK_GLYCOLYSIS
chr17:62449407-62450854:+
TGCTEERIRENSG00000130821.11chrX153691974:153692107:153693040:1536931750.30044.5718e-021.6660e-060.4245imageNNNAB_cells_naiveGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

More results



Top

5. Enriched editing regions and immune infiltration for METTL2A


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr17:62449407-62450854:+ACCEERNK_cells_resting4.3975e-02-0.2921image
ENSG00000087995.14,METTL2AACCEAGNK_cells_resting4.3975e-02-0.2921image
chr17:62449407-62450854:+BLCAEERMacrophages_M12.0172e-020.1359image
ENSG00000087995.14,METTL2ABLCAEAGMacrophages_M12.1884e-020.1339image
chr17:62449407-62450854:+BRCAEERDendritic_cells_resting2.1626e-020.0723image
ENSG00000087995.14,METTL2ABRCAEAGDendritic_cells_resting3.0244e-020.0681image
chr17:62449407-62450854:+CESCEERT_cells_gamma_delta3.5782e-020.1305image
chr17:62449407-62450854:+CHOLEERMacrophages_M13.9538e-020.3843image
ENSG00000087995.14,METTL2ACHOLEAGMacrophages_M14.2876e-020.3721image
chr17:62449407-62450854:+COADEERMonocytes6.7339e-03-0.1794image
ENSG00000087995.14,METTL2ACOADEAGMonocytes6.5409e-03-0.1788image
ENSG00000087995.14,METTL2ADLBCEAGDendritic_cells_activated2.6768e-030.5643image
chr17:62449407-62450854:+ESCAEERMacrophages_M21.1643e-020.2055image
ENSG00000087995.14,METTL2AESCAEAGMacrophages_M21.9259e-020.1903image
chr17:62449407-62450854:+GBMEERMacrophages_M18.0579e-030.2069image
ENSG00000087995.14,METTL2AGBMEAGMacrophages_M18.2766e-030.2062image
chr17:62449407-62450854:+HNSCEERT_cells_regulatory_(Tregs)1.5556e-02-0.1337image
ENSG00000087995.14,METTL2AHNSCEAGT_cells_regulatory_(Tregs)3.1205e-02-0.1186image
chr17:62449407-62450854:+KIRCEERT_cells_regulatory_(Tregs)1.9236e-030.1664image
ENSG00000087995.14,METTL2AKIRCEAGT_cells_regulatory_(Tregs)1.6131e-030.1687image
chr17:62449407-62450854:+KIRPEERT_cells_CD82.1796e-030.1911image
ENSG00000087995.14,METTL2AKIRPEAGT_cells_CD81.7646e-030.1949image
chr17:62449407-62450854:+LGGEERMacrophages_M12.5134e-020.0974image
ENSG00000087995.14,METTL2ALGGEAGMacrophages_M21.1538e-02-0.1099image
chr17:62449407-62450854:+LUADEERT_cells_follicular_helper4.5409e-03-0.1377image
ENSG00000087995.14,METTL2ALUADEAGT_cells_follicular_helper5.9848e-03-0.1333image
chr17:62449407-62450854:+LUSCEERMast_cells_resting3.7918e-02-0.1077image
ENSG00000087995.14,METTL2AOVEAGDendritic_cells_activated4.2795e-020.1227image
chr17:62449407-62450854:+PAADEERT_cells_follicular_helper2.8379e-03-0.2713image
ENSG00000087995.14,METTL2APAADEAGT_cells_follicular_helper4.0838e-03-0.2603image
chr17:62449407-62450854:+PCPGEERT_cells_CD82.3960e-020.1837image
ENSG00000087995.14,METTL2APCPGEAGT_cells_CD83.8226e-020.1688image
chr17:62449407-62450854:+PRADEERB_cells_naive9.1542e-030.1232image
ENSG00000087995.14,METTL2APRADEAGB_cells_naive9.9087e-030.1216image
chr17:62449407-62450854:+SKCMEERNK_cells_resting1.9074e-02-0.1163image
ENSG00000087995.14,METTL2ASKCMEAGNK_cells_resting2.0154e-02-0.1153image
chr17:62449407-62450854:+STADEERMonocytes4.5492e-110.3557image
ENSG00000087995.14,METTL2ASTADEAGMonocytes3.5597e-100.3389image
chr17:62449407-62450854:+TGCTEERMacrophages_M21.7422e-02-0.2132image
ENSG00000087995.14,METTL2ATGCTEAGMacrophages_M22.0453e-02-0.2080image
chr17:62449407-62450854:+THCAEERMast_cells_activated3.3630e-020.0991image
ENSG00000087995.14,METTL2ATHCAEAGMast_cells_activated4.3347e-020.0941image
chr17:62449407-62450854:+THYMEERMacrophages_M19.1035e-030.2663image
ENSG00000087995.14,METTL2ATHYMEAGMacrophages_M15.3785e-030.2834image
chr17:62449407-62450854:+UCECEERDendritic_cells_resting2.3167e-02-0.1866image
ENSG00000087995.14,METTL2AUCECEAGDendritic_cells_activated6.6185e-030.2223image
chr17:62449407-62450854:+UCSEERMacrophages_M14.8518e-030.3813image
ENSG00000087995.14,METTL2AUCSEAGMacrophages_M14.8518e-030.3813image


Top

6. Enriched editing regions and immune gene sets for METTL2A


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000087995.14,METTL2ABLCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.5936e-020.1301image
chr17:62449407-62450854:+BLCAGSVA_HALLMARK_KRAS_SIGNALING_DNEER2.6874e-020.1295image
chr17:62449407-62450854:+BRCAGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER8.4611e-060.1397image
ENSG00000087995.14,METTL2ABRCAGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG3.9659e-050.1288image
chr17:62449407-62450854:+CESCGSVA_HALLMARK_APOPTOSISEER9.2160e-050.2406image
ENSG00000087995.14,METTL2ACESCGSVA_HALLMARK_P53_PATHWAYEAG1.9568e-040.2290image
ENSG00000087995.14,METTL2ACHOLGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG4.5723e-020.3675image
chr17:62449407-62450854:+COADGSVA_HALLMARK_ANGIOGENESISEER6.7568e-040.2240image
ENSG00000087995.14,METTL2ACOADGSVA_HALLMARK_ANGIOGENESISEAG1.3020e-030.2108image
ENSG00000087995.14,METTL2ADLBCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG3.1747e-030.5562image
ENSG00000087995.14,METTL2AESCAGSVA_HALLMARK_BILE_ACID_METABOLISMEAG3.7868e-03-0.2343image
chr17:62449407-62450854:+ESCAGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER3.0301e-030.2405image
chr17:62449407-62450854:+GBMGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER6.9757e-040.2629image
ENSG00000087995.14,METTL2AGBMGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG8.7261e-040.2583image
ENSG00000087995.14,METTL2AHNSCGSVA_HALLMARK_KRAS_SIGNALING_DNEAG6.4893e-040.1868image
chr17:62449407-62450854:+HNSCGSVA_HALLMARK_APICAL_JUNCTIONEER2.3530e-040.2020image
ENSG00000087995.14,METTL2AKICHGSVA_HALLMARK_ANDROGEN_RESPONSEEAG4.5830e-020.3350image
chr17:62449407-62450854:+KICHGSVA_HALLMARK_ANDROGEN_RESPONSEEER4.5830e-020.3350image
chr17:62449407-62450854:+KIRCGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER2.2043e-020.1232image
ENSG00000087995.14,METTL2AKIRCGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEAG2.5176e-020.1202image
ENSG00000087995.14,METTL2AKIRPGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG6.8106e-03-0.1691image
chr17:62449407-62450854:+KIRPGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER8.8260e-03-0.1637image
ENSG00000087995.14,METTL2ALGGGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG2.6796e-060.2026image
chr17:62449407-62450854:+LGGGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER4.4126e-060.1983image
ENSG00000087995.14,METTL2ALUADGSVA_HALLMARK_ANGIOGENESISEAG1.0904e-030.1581image
chr17:62449407-62450854:+LUADGSVA_HALLMARK_ANGIOGENESISEER1.4821e-040.1834image
chr17:62449407-62450854:+LUSCGSVA_HALLMARK_MYC_TARGETS_V1EER7.1387e-04-0.1747image
ENSG00000087995.14,METTL2ALUSCGSVA_HALLMARK_MYC_TARGETS_V1EAG9.3108e-04-0.1705image
chr17:62449407-62450854:+MESOGSVA_HALLMARK_MYOGENESISEER1.1678e-02-0.2957image
ENSG00000087995.14,METTL2AMESOGSVA_HALLMARK_MYOGENESISEAG1.7263e-02-0.2799image
chr17:62449407-62450854:+OVGSVA_HALLMARK_KRAS_SIGNALING_DNEER2.8288e-020.1328image
ENSG00000087995.14,METTL2APAADGSVA_HALLMARK_DNA_REPAIREAG9.5621e-03-0.2357image
chr17:62449407-62450854:+PAADGSVA_HALLMARK_DNA_REPAIREER1.2085e-03-0.2933image
ENSG00000087995.14,METTL2APCPGGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG3.5695e-02-0.1711image
ENSG00000087995.14,METTL2APRADGSVA_HALLMARK_UV_RESPONSE_DNEAG9.5442e-040.1554image
chr17:62449407-62450854:+PRADGSVA_HALLMARK_UV_RESPONSE_DNEER6.4158e-040.1608image
chr17:62449407-62450854:+SARCGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER4.6542e-040.2489image
ENSG00000087995.14,METTL2ASARCGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG1.0841e-030.2329image
chr17:62449407-62450854:+SKCMGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER1.0793e-020.1264image
ENSG00000087995.14,METTL2ASKCMGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.4060e-020.1218image
chr17:62449407-62450854:+STADGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER1.0574e-030.1814image
ENSG00000087995.14,METTL2ASTADGSVA_HALLMARK_BILE_ACID_METABOLISMEAG4.0434e-030.1591image
ENSG00000087995.14,METTL2ATGCTGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG2.2649e-03-0.2718image
chr17:62449407-62450854:+TGCTGSVA_HALLMARK_GLYCOLYSISEER1.7542e-03-0.2782image
ENSG00000087995.14,METTL2ATHCAGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.9634e-03-0.1438image
chr17:62449407-62450854:+THCAGSVA_HALLMARK_PANCREAS_BETA_CELLSEER2.0665e-03-0.1433image
chr17:62449407-62450854:+THYMGSVA_HALLMARK_PROTEIN_SECRETIONEER1.7123e-030.3176image
ENSG00000087995.14,METTL2ATHYMGSVA_HALLMARK_PROTEIN_SECRETIONEAG9.8226e-040.3328image
chr17:62449407-62450854:+UCECGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER5.1200e-03-0.2290image
ENSG00000087995.14,METTL2AUCECGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.7302e-02-0.1954image


Top

7. Enriched editing regions and drugs for METTL2A


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000087995.14,METTL2AACCJNK.9LEAG4.4104e-020.2919image
chr17:62449407-62450854:+ACCJNK.9LEER4.4104e-020.2919image
ENSG00000087995.14,METTL2ABLCAAZD.0530EAG1.6575e-03-0.1830image
chr17:62449407-62450854:+BLCAAZD.0530EER1.1047e-03-0.1900image
ENSG00000087995.14,METTL2ABRCAEHT.1864EAG3.7928e-060.1447image
chr17:62449407-62450854:+BRCAEHT.1864EER1.1156e-060.1526image
ENSG00000087995.14,METTL2ACESCAxitinibEAG1.7004e-030.1937image
chr17:62449407-62450854:+CESCElesclomolEER2.4501e-030.1875image
ENSG00000087995.14,METTL2ACOADJNJ.26854165EAG7.2715e-05-0.2585image
chr17:62449407-62450854:+COADJNJ.26854165EER2.3769e-04-0.2416image
ENSG00000087995.14,METTL2ADLBCKIN001.135EAG1.9456e-03-0.5789image
chr17:62449407-62450854:+ESCAAMG.706EER2.3374e-03-0.2475image
ENSG00000087995.14,METTL2AESCAAMG.706EAG2.4079e-03-0.2460image
ENSG00000087995.14,METTL2AGBMAZD.0530EAG7.1304e-05-0.3060image
chr17:62449407-62450854:+GBMAZD.0530EER6.1193e-05-0.3086image
ENSG00000087995.14,METTL2AHNSCImatinibEAG4.2572e-05-0.2233image
chr17:62449407-62450854:+HNSCImatinibEER7.2631e-06-0.2452image
chr17:62449407-62450854:+KICHGDC.0449EER9.3920e-030.4270image
ENSG00000087995.14,METTL2AKICHGDC.0449EAG9.3920e-030.4270image
chr17:62449407-62450854:+KIRCJNJ.26854165EER9.2084e-04-0.1776image
ENSG00000087995.14,METTL2AKIRCJNJ.26854165EAG7.2127e-04-0.1807image
ENSG00000087995.14,METTL2AKIRPFTI.277EAG4.7913e-040.2171image
chr17:62449407-62450854:+KIRPFTI.277EER6.4656e-040.2122image
ENSG00000087995.14,METTL2ALGGGSK.650394EAG2.1096e-060.2047image
chr17:62449407-62450854:+LGGGSK.650394EER1.0094e-060.2109image
ENSG00000087995.14,METTL2ALIHCAUY922EAG1.2635e-02-0.1756image
chr17:62449407-62450854:+LIHCKIN001.135EER3.4844e-03-0.2051image
chr17:62449407-62450854:+LUADAZD6482EER2.7710e-03-0.1453image
ENSG00000087995.14,METTL2ALUADAZD6482EAG3.4370e-03-0.1420image
chr17:62449407-62450854:+LUSCLFM.A13EER5.6929e-04-0.1778image
ENSG00000087995.14,METTL2ALUSCGW.441756EAG2.1859e-040.1900image
chr17:62449407-62450854:+MESOCEP.701EER4.0956e-030.3344image
ENSG00000087995.14,METTL2AMESOAMG.706EAG4.0339e-03-0.3349image
ENSG00000087995.14,METTL2AOVAZD8055EAG1.5275e-030.1909image
chr17:62449407-62450854:+OVEtoposideEER1.8818e-030.1873image
chr17:62449407-62450854:+PAADCHIR.99021EER4.5853e-04-0.3215image
ENSG00000087995.14,METTL2APAADLapatinibEAG2.4059e-04-0.3389image
chr17:62449407-62450854:+PCPGBortezomibEER3.8323e-020.1688image
ENSG00000087995.14,METTL2APCPGBortezomibEAG2.1538e-020.1869image
chr17:62449407-62450854:+PRADCCT007093EER4.6778e-05-0.1913image
ENSG00000087995.14,METTL2APRADCCT007093EAG1.0792e-04-0.1817image
ENSG00000087995.14,METTL2AREADJNK.Inhibitor.VIIIEAG3.1991e-02-0.2315image
chr17:62449407-62450854:+READJNK.Inhibitor.VIIIEER2.6934e-02-0.2386image
ENSG00000087995.14,METTL2ASARCAZD.0530EAG2.1284e-02-0.1653image
chr17:62449407-62450854:+SARCBIRB.0796EER9.2519e-030.1864image
chr17:62449407-62450854:+SKCMCMKEER6.8712e-030.1340image
ENSG00000087995.14,METTL2ASKCMCMKEAG7.9678e-030.1315image
ENSG00000087995.14,METTL2ASTADCGP.60474EAG1.8781e-180.4604image
chr17:62449407-62450854:+STADCGP.60474EER2.7761e-190.4715image
chr17:62449407-62450854:+TGCTDocetaxelEER8.7431e-050.3449image
ENSG00000087995.14,METTL2ATGCTDocetaxelEAG1.5276e-040.3336image
chr17:62449407-62450854:+THCABIBW2992EER1.8314e-02-0.1100image
chr17:62449407-62450854:+THYMBMS.509744EER1.0554e-030.3309image
ENSG00000087995.14,METTL2ATHYMBMS.509744EAG8.4320e-040.3369image
chr17:62449407-62450854:+UCECBortezomibEER1.2338e-020.2052image
ENSG00000087995.14,METTL2AUCECBortezomibEAG3.6050e-020.1725image
chr17:62449407-62450854:+UCSCCT018159EER2.1833e-020.3145image
ENSG00000087995.14,METTL2AUCSCCT018159EAG2.1833e-020.3145image
chr17:62449407-62450854:+UVMBMS.536924EER7.5767e-03-0.3629image
ENSG00000087995.14,METTL2AUVMBMS.536924EAG7.5767e-03-0.3629image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType